Amyloid Beta-Peptide (1-40) (human): Structure, Function,...
Amyloid Beta-Peptide (1-40) (human): Structure, Function, and Benchmarks for Alzheimer's Disease Research
Executive Summary: Amyloid Beta-Peptide (1-40) (human) is a 40-amino acid synthetic peptide corresponding to residues 1–40 of the human amyloid-beta sequence, central to Alzheimer's disease pathology (Kwon et al. 2024). Aβ(1-40) is derived from the amyloid precursor protein (APP) via β- and γ-secretase cleavage and is a major constituent of amyloid plaques (APExBIO). It modulates neuronal calcium channel activity and inhibits acetylcholine release in animal models, providing a validated neurotoxicity model. Recent studies reveal Aβ(1-40) also regulates microglial activity and brain development, complicating its biological interpretation. This article integrates structural, mechanistic, and experimental benchmarks to guide rigorous use in Alzheimer's disease research.
Biological Rationale
Amyloid Beta-Peptide (1-40) (human) (Aβ(1-40)) is a predominant isoform of amyloid-beta peptides found in human brain tissue. It is produced by sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretases, mainly in the Golgi apparatus (Kwon et al. 2024). Aβ(1-40) accumulates extracellularly, forming plaques and vascular deposits that are characteristic of Alzheimer's disease pathology (see also). Compared to the longer Aβ(1-42) variant, Aβ(1-40) is more abundant but less prone to aggregation under physiological conditions. Its relative solubility and lower oligomerization propensity make it a preferred model for mechanistic and therapeutic studies (contrast: membrane interaction focus).
Mechanism of Action of Amyloid Beta-Peptide (1-40) (human)
Aβ(1-40) exerts multiple effects at the molecular and cellular levels. In neurons, it modulates calcium channel activity, specifically increasing barium current (IBa) in hippocampal CA1 pyramidal neurons in a voltage-dependent manner (APExBIO). In animal models, intraperitoneal injection of Aβ(1-40) significantly reduces both basal and stimulated acetylcholine release, mirroring cholinergic deficits observed in Alzheimer's disease (Kwon et al. 2024). At the microglial level, recent evidence demonstrates that monomeric Aβ(1-40) inhibits microglial immune activation by engaging a pathway dependent on APP and the G-protein regulator Ric8a. Genetic disruption of this pathway during development results in microglial dysregulation, excessive matrix metalloproteinase activation, and abnormal neuronal migration (Kwon et al. 2024). Thus, Aβ(1-40) participates in both pathological and physiological brain processes.
Evidence & Benchmarks
- Aβ(1-40) forms amyloid fibrils in vitro under physiological temperature and pH, serving as a robust model for amyloidogenesis (Kwon et al. 2024).
- In hippocampal neurons, Aβ(1-40) increases IBa in a voltage-dependent manner, providing a mechanistic link to calcium dysregulation in Alzheimer's disease (APExBIO).
- Intraperitoneal injection of Aβ(1-40) (1–10 μM, in saline) in rats significantly decreases acetylcholine release in the cortex, modeling neurodegenerative deficits (Kwon et al. 2024).
- Monomeric Aβ(1-40) inhibits microglial immune activation at transcriptional and post-transcriptional levels in mouse models (Kwon et al. 2024).
- Genetic disruption of APP or Ric8a abolishes Aβ(1-40)–mediated regulation of microglia, resulting in laminar disruption during cortical development (see Table 1, Kwon et al. 2024).
Applications, Limits & Misconceptions
Applications:
- Modeling amyloid fibril formation and aggregation kinetics under controlled laboratory conditions (see also).
- Investigating neurotoxicity mechanisms, specifically synaptic dysfunction and calcium channel modulation (complement: workflow innovation).
- Screening anti-amyloid therapeutics by quantifying peptide aggregation or toxicity endpoints.
- Studying physiological and pathological effects of Aβ on glial signaling, particularly in microglia (Kwon et al. 2024).
Limits & Misconceptions:
Common Pitfalls or Misconceptions
- Not a diagnostic or medical product: Amyloid Beta-Peptide (1-40) (human) from APExBIO is intended strictly for research use only (APExBIO).
- Solubility constraints: The peptide is insoluble in ethanol and must be dissolved in water or DMSO at specified concentrations (≥23.8 mg/mL in water, ≥43.28 mg/mL in DMSO).
- Long-term storage risk: Stock solutions should not be stored long-term; aliquot and freeze at -80°C for optimal stability.
- Physiological relevance: Over-aggregation or high concentrations may not accurately reflect in vivo conditions, leading to artifactual results.
- Sequence limitations: Aβ(1-40) lacks the two C-terminal residues of Aβ(1-42), resulting in distinct aggregation and toxicity profiles.
Workflow Integration & Parameters
For experimental use, Amyloid Beta-Peptide (1-40) (human) should be reconstituted in sterile water at concentrations above 10 mM. After reconstitution, aliquot and store at -80°C in desiccated conditions to preserve peptide integrity for several months. Avoid repeated freeze-thaw cycles. The peptide is best solubilized in water or DMSO, not ethanol. For cell-based assays, pre-aggregation protocols (e.g., incubation at 37°C for 24–48 h in PBS) may be used to generate fibrillar or oligomeric forms. Use freshly prepared solutions to ensure reproducibility. For detailed scenario-based laboratory guidance, see workflow troubleshooting resource—this article builds on those protocols by clarifying microglial signaling and calcium channel endpoints.
Conclusion & Outlook
Amyloid Beta-Peptide (1-40) (human) (SKU A1124) from APExBIO remains a gold-standard reagent for modeling amyloidogenesis, neurotoxicity, and microglial signaling in Alzheimer's disease research. Its defined sequence, validated benchmarks, and robust experimental protocols ensure reproducibility. However, its multifaceted biological roles—including emerging evidence for microglial regulation—necessitate careful interpretation of results. Future research should address the physiological versus pathological effects of Aβ(1-40) and optimize model selection for translational studies. For detailed product information and ordering, visit Amyloid Beta-Peptide (1-40) (human) product page.